Breaking News

ADC Therapeutics, SOPHiA GENETICS Partner for Biomarker Discovery

Pivotal Phase II trial to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in DLBCL

ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently evaluating ADCT-402 in a Phase II trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).   SOPHiA technology will match detected genomic markers with clinical response to ADCT-402. The analytical power of SOPHiA will be leveraged for the detection of cancer mutations...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters